Novel atpase inhibitor

Abstract

The invention provides a novel human ATPase inhibitor protein (HATPI) and polynucleotides which identify and encode HATPI. The invention also provides genetically engineered expression vectors and host cells containing the nucleic acid sequences encoding HATPI. The invention also provides pharmaceutical compositions containing HATPI or antagonists to HATPI, and in the use of these compositions for the treatment of diseases associated with the expression of HATPI. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HATPI for the treatment of diseases associated with the expression of HATPI. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HATPI or anti-HATPI antibodies which specifically bind to HATPI.

1 . A substantially purified human ATPase inhibitor protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.  
     
     
         2 . An isolated and purified polynucleotide sequence encoding the protein of  claim 1 .  
     
     
         3 . An isolated and purified polynucleotide sequence of  claim 2  consisting of SEQ ID NO:2 or variants thereof.  
     
     
         4 . A polynucleotide sequence which is complementary to SEQ ID NO:2 or variants thereof.  
     
     
         5 . A recombinant expression vector containing the polynucleotide sequence of  claim 2 .  
     
     
         6 . A recombinant host cell containing the vector of  claim 5 .  
     
     
         7 . A method for producing a polypeptide comprising a polypeptide of SEQ ID NO:1, the method comprising the steps of: 
 a) culturing the host cell of  claim 6  under conditions suitable for the expression of the polypeptide; and    b) recovering the polypeptide from the host cell culture.    
     
     
         8 . A pharmaceutical composition comprising a substantially purified human ATPase inhibitor protein having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.  
     
     
         9 . A purified antibody which binds specifically to the polypeptide of  claim 1 .  
     
     
         10 . A purified antagonist which specifically inhibits the activity of the polypeptide of  claim 1 .  
     
     
         11 . A pharmaceutical composition comprising the antagonist of  claim 10  in conjunction with a suitable pharmaceutical carrier.  
     
     
         12 . A method for treating ischemia comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim  11 .